UnitedHealth Group Inc. Stock
€262.95
Your prediction
UnitedHealth Group Inc. Stock
Pros and Cons of UnitedHealth Group Inc. in the next few years
Pros
Cons
Performance of UnitedHealth Group Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| UnitedHealth Group Inc. | 0.060% | -0.398% | -0.114% | -42.279% | -45.878% | -46.965% | -1.295% |
| Centene Corp. | 1.630% | -37.676% | -40.285% | -53.502% | -50.017% | -65.126% | -51.428% |
| Humana Inc. | -0.540% | -2.372% | -0.297% | -40.219% | -16.893% | -55.961% | -42.371% |
| Cigna Corp. | -0.130% | -2.780% | 0.442% | -9.414% | 3.099% | 6.169% | 60.471% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.When evaluating the financials of UnitedHealth Group (UNH), it becomes apparent that this company stands as a formidable entity within the Healthcare Providers & Services industry. The metrics and trends presented in the financial statements, alongside the ratios provided, paint a picture of robust growth prospects, operational efficiency, and a sound balance sheet. However, not all appears pristine; there are nuances worth exploring that highlight both strengths and potential pitfalls.
Pros of UnitedHealth's Financials
Strong Revenue Streams: UnitedHealth has consistently shown impressive revenue growth, with total revenues amounting to approximately $385.44 billion over the last twelve months. The company's ability to generate significant top-line revenue is indicative of its market strength and wide-ranging service offerings.
Comments
News
Best Stocks to Buy: Hims & Hers Stock vs. UnitedHealth Stock
Hims & Hers (NYSE: HIMS) and UnitedHealth (NYSE: UNH) suffered huge stock price decreases that attracted investors looking to buy the dip.
*Stock prices used were the afternoon prices of June 28
These 3 Stocks Have Been the Worst Performers in the S&P 500 This Year. Have They Bottomed Out?
The threat of tariffs and trade wars sank many stocks back in April, but the market managed a sharp turnaround since then, reminiscent of the brief pandemic crash five years earlier. Many stocks are
This Dirt Cheap Healthcare Stock Could Be a Hidden Artificial Intelligence (AI) Opportunity (Hint: It's Not Eli Lilly)
When it comes to popular healthcare stocks, investors have focused a lot of attention lately on Eli Lilly and Novo Nordisk and the potential of their blockbuster weight management treatments